A detailed history of Brinker Capital Investments, LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Brinker Capital Investments, LLC holds 19,141 shares of BMRN stock, worth $1.28 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
19,141
Previous 21,024 8.96%
Holding current value
$1.28 Million
Previous $1.78 Million 11.11%
% of portfolio
0.04%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

SELL
$80.93 - $108.63 $152,391 - $204,550
-1,883 Reduced 8.96%
19,141 $1.98 Million
Q3 2022

Nov 01, 2022

BUY
$82.16 - $96.94 $4,600 - $5,428
56 Added 0.27%
21,024 $1.78 Million
Q2 2022

Jul 18, 2022

BUY
$71.48 - $86.85 $316,227 - $384,224
4,424 Added 26.74%
20,968 $1.74 Million
Q1 2022

May 16, 2022

BUY
$74.28 - $92.69 $356,321 - $444,633
4,797 Added 40.84%
16,544 $1.28 Million
Q4 2021

Feb 08, 2022

SELL
$71.72 - $91.47 $1.05 Million - $1.34 Million
-14,626 Reduced 55.46%
11,747 $1.04 Million
Q2 2021

Aug 03, 2021

BUY
$75.51 - $84.79 $341,380 - $383,335
4,521 Added 20.69%
26,373 $2.2 Million
Q1 2021

May 12, 2021

SELL
$74.73 - $90.69 $1.64 Million - $1.99 Million
-21,934 Reduced 50.09%
21,852 $1.65 Million
Q4 2020

Feb 16, 2021

BUY
$72.61 - $90.2 $1.82 Million - $2.26 Million
25,097 Added 134.29%
43,786 $3.84 Million
Q3 2020

Dec 03, 2020

BUY
$71.87 - $131.03 $1.34 Million - $2.45 Million
18,689 New
18,689 $1.42 Million
Q4 2019

Feb 06, 2020

SELL
$64.27 - $86.37 $4,948 - $6,650
-77 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$67.4 - $85.11 $5,189 - $6,553
77 New
77 $5,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Brinker Capital Investments, LLC Portfolio

Follow Brinker Capital Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brinker Capital Investments, LLC with notifications on news.